This Οργανισμός is not specific to Greece. For more details, please visit OpenAIRE Explore.

Last update of records in OpenAIRE: Aug 12, 2026

Found an issue? Give us feedback

corporate_fareOrganisationResearchNon-Profit

UNICANCER

Organisation website

Location

location_onFrance

Identifiers

Projects(13)

assignment_turned_inProjectOpen Access Mandate for Publications and Datasets
INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL (DE-ESCALATE)
Ongoing
Jun 2023 - May 2028
European CommissionHEOverall Budget: €7,185,660.00 Funder contribution: €7,185,660.00 Grant: HORIZON-MISS-2022-CANCER-01-101104574
Pragmatic clinical trials to optimise treatments for patients with refractory cancers
Partners: UNICANCER EUROPA UOMO ICORG EORTC 2 more
location_on France Belgium Ireland Hungary Spain
DOI: 10.3030/101104574
assignment_turned_inProjectOpen Access Mandate for Publications and Datasets
Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer (DEFINITIVE)
Ongoing
Dec 2023 - Nov 2028
European CommissionHEOverall Budget: €7,999,930.00 Funder contribution: €7,999,930.00 Grant: HORIZON-MISS-2023-CANCER-01-101136953
Pragmatic clinical trials on minimally invasive diagnostics
Partners: Sheba Research Fund Medical University of Vienna UCC EUR 10 more
location_on Israel Austria Ireland Netherlands 4 more
DOI: 10.3030/101136953
assignment_turned_inProjectOpen Access Mandate for Publications and Datasets
PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification (PRE-ACT)
Ongoing
Oct 2022 - Sep 2027
European CommissionHEOverall Budget: €4,596,620.00 Funder contribution: €4,592,120.00 Grant: HORIZON-HLTH-2021-DISEASE-04-101057746
Clinical validation of artificial intelligence (AI) solutions for treatment and care
Partners: AUEB-RC UNICANCER UM ISI 5 more
location_on Greece France Netherlands Italy
DOI: 10.3030/101057746
assignment_turned_inProjectOpen Access Mandate for Publications and Datasets
Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH)
Ongoing
May 2025 - Apr 2031
European CommissionHEOverall Budget: €14,037,500.00 Funder contribution: €13,606,300.00 Grant: HORIZON-MISS-2024-CANCER-01-101213916
Accessible and affordable tests to advance early detection of heritable cancers in European regions
Partners: RSU MSInsight KBCSM EUREGHA - European regional and local he... 24 more
location_on Latvia France Croatia Belgium 11 more
DOI: 10.3030/101213916
assignment_turned_inProjectOpen Access Mandate for Publications and Datasets
OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS (OASIS)
Ongoing
Jan 2025 - Dec 2029
European CommissionHEFunder contribution: €9,941,530.00 Grant: HORIZON-HLTH-2024-TOOL-05-two-stage-101156771
Innovative non-animal human-based tools and strategies for biomedical research
Partners: UNICANCER Institut Gustave Roussy UOA (ΕΚΠΑ) CANCER PATIENTS EUROPE 8 more
location_on France Greece Belgium Sweden
DOI: 10.3030/101156771

chevron_left
1
2
3
chevron_right

UNICANCER

Projects(13)

INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL (DE-ESCALATE)
Ongoing

Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer (DEFINITIVE)
Ongoing

PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification (PRE-ACT)
Ongoing

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH)
Ongoing

OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS (OASIS)
Ongoing

Data sources

Recent Publications

Recent Research data

Recent Research software

Recent Other research products

Parent Organisations

Child Organisations

Versions (2)

UNICANCER

UNICANCER

Research Footprint

Total research products

Research products

Openness

Fields of Science

SDGs

Data Sources

Projects

Dashboard

Resources

Service

UNICANCER

Projects(13)

INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL (DE-ESCALATE)Ongoing

Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer (DEFINITIVE)Ongoing

PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification (PRE-ACT)Ongoing

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH)Ongoing

OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS (OASIS)Ongoing

Data sources

Recent Publications

Recent Research data

Recent Research software

Recent Other research products

Parent Organisations

Child Organisations

Versions (2)

UNICANCER

UNICANCER

Research Footprint

Total research products

Research products

Openness

Fields of Science

SDGs

Data Sources

Projects

Loading

INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL (DE-ESCALATE)
Ongoing

Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer (DEFINITIVE)
Ongoing

PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification (PRE-ACT)
Ongoing

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH)
Ongoing

OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS (OASIS)
Ongoing